Company news
Ardelyx, Inc. (NASDAQ:ARDX) news
Ardelyx, Inc. news releases on 6ix. Latest, Oct 5, 2026: Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
Press releases & updates
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
October 5, 2026
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
October 4, 2026
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
September 30, 2026
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
September 29, 2026
Ardelyx : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
May 19, 2026
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
May 7, 2026
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
April 27, 2026
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
April 23, 2026
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
April 20, 2026
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
April 16, 2026
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
March 31, 2026
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
March 11, 2026
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
March 8, 2026
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
March 5, 2026
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
February 23, 2026
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 19, 2026
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
February 4, 2026
Ardelyx Receives New Patent for Tenapanor
February 3, 2026
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 28, 2026
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
January 8, 2026
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
November 6, 2025
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
November 4, 2025
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
November 3, 2025
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 29, 2025
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
October 27, 2025
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
October 20, 2025
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
October 12, 2025
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
October 12, 2025
Ardelyx to Participate in Upcoming Investor Conferences
August 24, 2025
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors
August 12, 2025
Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
August 3, 2025
Ardelyx Announces Changes to the Executive Leadership Team
August 3, 2025
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
July 20, 2025
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
June 1, 2025
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
May 20, 2025
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
May 5, 2025
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
April 30, 2025
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
April 28, 2025
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
April 23, 2025
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
April 16, 2025
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
April 9, 2025
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
March 30, 2025
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
March 12, 2025
Tenapanor Approved in China for Hyperphosphatemia
February 26, 2025
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 19, 2025
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
February 18, 2025